<div id="readability-page-1"><p>Vontobel Holding Ltd. lifted its position in shares of  Natera, Inc. (NASDAQ:NTRA - Free Report) by 192.5% in the third quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The fund owned 8,531 shares of the medical research company's stock after buying an additional 5,614 shares during the period. Vontobel Holding Ltd.'s holdings in Natera were worth $1,373,000 as of its most recent SEC filing.</p><ul><li>3 Under-the-Radar Healthcare Companies</li></ul><p>A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase &amp; Co. increased its stake in  Natera by 44.3% during the second quarter. JPMorgan Chase &amp; Co. now owns 10,625,785 shares of the medical research company's stock worth $1,795,125,000 after acquiring an additional 3,263,822 shares during the last quarter.  Norges Bank acquired a new position in shares of  Natera in the 2nd quarter valued at about $277,749,000.  UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of  Natera by 140.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company's stock worth $177,298,000 after purchasing an additional 732,156 shares during the period.  AQR Capital Management LLC increased its position in  Natera by 44.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,726,750 shares of the medical research company's stock worth $291,717,000 after purchasing an additional 532,769 shares in the last quarter.  Finally, Ninety One UK Ltd raised its holdings in  Natera by 149.1% in the second quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company's stock valued at $95,111,000 after buying an additional 336,985 shares during the period. Institutional investors and hedge funds own  99.90% of the company's stock. </p><h2>Insider Buying and Selling</h2><p>In related news, Director Roy D. Baynes sold 7,668 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $223.08, for a total transaction of $1,710,577.44. Following the sale, the director owned 18,359 shares in the company, valued at $4,095,525.72. This represents a 29.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, Director Herm Rosenman sold 48,419 shares of the firm's stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $227.42, for a total transaction of $11,011,448.98. Following the completion of the transaction, the director directly owned 20,342 shares in the company, valued at $4,626,177.64. This represents a 70.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 365,164 shares of company stock worth $76,621,909. Company insiders own  5.63% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li></ul><p>Several equities research analysts have issued reports on the stock. Evercore ISI boosted their price objective on shares of Natera from $190.00 to $250.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, November 7th. Piper Sandler upped their price target on shares of Natera from $220.00 to $230.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, November 11th. Royal Bank Of Canada  set a $268.00 price objective on Natera and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, September 2nd. Canaccord Genuity Group boosted their price objective on Natera from $250.00 to $285.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, December 22nd. Finally, JPMorgan Chase &amp; Co. increased their target price on Natera from $250.00 to $260.00 and gave the company an &#34;overweight&#34; rating in a research note on Monday, December 15th. Fifteen analysts have rated the stock with a Buy rating, three have assigned  a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $231.18.</p><p><b>Get Our Latest Stock Analysis on NTRA</b></p><h2>Natera Trading Down 0.8%</h2><p>Shares of NTRA opened at $233.74 on Friday. The firm has a market cap of $32.33 billion, a price-to-earnings ratio of -102.07 and a beta of 1.63. The stock has a 50 day moving average of $218.14 and a 200-day moving average of $181.47. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $246.90. </p><p>Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same period in the prior year, the company posted ($0.26) earnings per share. The business's revenue was up 34.7% on a year-over-year basis.  On average, sell-side analysts predict that  Natera, Inc. will post -1.49 earnings per share for the current fiscal year. </p><h2>About Natera</h2> (Free Report)<p>Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.  </p><p>Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Natera</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>The Best $1 You'll Spend This Holiday Season</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>The $650 Million Bet on AI's Future</li><li>Nvidia x 1,000,000</li></ul><p><strong>Want to see what other hedge funds are holding NTRA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Natera Right Now?</h2><p>Before you consider Natera, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.</p><p>While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

NTRA

<p>Vontobel Holding Ltd. increased its stake in Natera, Inc. by 192.5% in Q3, owning 8,531 shares worth $1,373,000. Other investors like JPMorgan Chase & Co. and UBS Asset Management also increased their positions. Analysts have given Natera a "Moderate Buy" rating with a consensus target price of $231.18. Natera's stock opened at $233.74, with a market cap of $32.33 billion.</p>

Vontobel Holding Ltd. Increases Stock Position in Natera, Inc. $NTRA